All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
HONG KONG – The R&D arm of a China-based health care group owned by the multinational conglomerate Hutchison Whampoa Ltd. (HK:13) has moved its leading oncology candidate into phase III.
